Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
Dilek Keskin, Sevil Sadri, Ahmet Emre Eskazan Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey Abstract: Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intoleranc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-10-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/dasatinib-for-the-treatment-of-chronic-myeloid-leukemia-patient-select-peer-reviewed-article-DDDT |
| _version_ | 1811234459409711104 |
|---|---|
| author | Keskin D Sadri S Eskazan AE |
| author_facet | Keskin D Sadri S Eskazan AE |
| author_sort | Keskin D |
| collection | DOAJ |
| description | Dilek Keskin, Sevil Sadri, Ahmet Emre Eskazan Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey Abstract: Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome-positive acute lymphocytic leukemia. While choosing the appropriate tyrosine kinase inhibitor (ie, dasatinib) for each individual patient, comorbidities and BCR-ABL1 kinase domain mutations should always be taken into consideration, among other things. This review mainly focuses on patient selection prior to dasatinib administration in the treatment of chronic myeloid leukemia. Keywords: chronic myeloid leukemia, comorbidity, dasatinib, mutation, tyrosine kinase inhibitor |
| first_indexed | 2024-04-12T11:37:52Z |
| format | Article |
| id | doaj.art-a4ba0a89e0a04e5cba157675a9a6c85d |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-12T11:37:52Z |
| publishDate | 2016-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-a4ba0a89e0a04e5cba157675a9a6c85d2022-12-22T03:34:48ZengDove Medical PressDrug Design, Development and Therapy1177-88812016-10-01Volume 103355336129412Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsKeskin DSadri SEskazan AEDilek Keskin, Sevil Sadri, Ahmet Emre Eskazan Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey Abstract: Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome-positive acute lymphocytic leukemia. While choosing the appropriate tyrosine kinase inhibitor (ie, dasatinib) for each individual patient, comorbidities and BCR-ABL1 kinase domain mutations should always be taken into consideration, among other things. This review mainly focuses on patient selection prior to dasatinib administration in the treatment of chronic myeloid leukemia. Keywords: chronic myeloid leukemia, comorbidity, dasatinib, mutation, tyrosine kinase inhibitor https://www.dovepress.com/dasatinib-for-the-treatment-of-chronic-myeloid-leukemia-patient-select-peer-reviewed-article-DDDTChronic myeloid leukemiacomorbiditydasatinibmutationtyrosine kinase inhibitor |
| spellingShingle | Keskin D Sadri S Eskazan AE Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations Drug Design, Development and Therapy Chronic myeloid leukemia comorbidity dasatinib mutation tyrosine kinase inhibitor |
| title | Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations |
| title_full | Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations |
| title_fullStr | Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations |
| title_full_unstemmed | Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations |
| title_short | Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations |
| title_sort | dasatinib for the treatment of chronic myeloid leukemia patient selection and special considerations |
| topic | Chronic myeloid leukemia comorbidity dasatinib mutation tyrosine kinase inhibitor |
| url | https://www.dovepress.com/dasatinib-for-the-treatment-of-chronic-myeloid-leukemia-patient-select-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT keskind dasatinibforthetreatmentofchronicmyeloidleukemiapatientselectionandspecialconsiderations AT sadris dasatinibforthetreatmentofchronicmyeloidleukemiapatientselectionandspecialconsiderations AT eskazanae dasatinibforthetreatmentofchronicmyeloidleukemiapatientselectionandspecialconsiderations |